Inclusion into China's national reimbursement drug list alone does not guarantee revenue growth but in some cases higher volumes seem to be offsetting the requisite big price cuts, reveal second-quarter results from some leading publicly-traded biotechs in the country.

Partners will share development and commercial rights to up to three ISAC products for cancer. Wockhardt licenses China rights for novel antibiotic to Jiangsu Jemincare.

Hugel says its longer-term global growth strategy will remain intact after a major acquisition of the Korean medical aesthetics company by a consortium including GS Group.

Despite a pending domestic approval for BioNTech/Fosun's COVID-19 vaccine, China’s apparent belief in another, domestically developed, mRNA vaccine sees a large group of investors pour hundreds of millions into a little-known private bioventure founded by an ex-Moderna scientist and poised to take on the US biotech.